SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on lupus in early trial
Disease control OngoingThis study tests a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE), an autoimmune disease. The treatment uses a patient's own immune cells that are modified in a lab to target and attack the faulty immune cells causing lupus. The main goals ar…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated May 17, 2026 00:29 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who already completed a previous study will continue taking the drug for up to 3 years, along with their usual medications. Researchers will track side effects and…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 17, 2026 00:29 UTC
-
New lupus drug candidate enters first human tests
Disease control OngoingThis early-stage study tests a new drug called KK4277 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body. The study does not aim to cure lupus, bu…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New lupus injection enters first human safety tests
Disease control OngoingThis study is an early test of an experimental drug called SG301, given as an injection under the skin. It will first be tested in 48 healthy adults to check safety, then in people with systemic lupus erythematosus (SLE), an autoimmune disease. The main goal is to see if the drug…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Experimental cell combo for lupus and scleroderma pulled before starting
Disease control TerminatedThis study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and inflammatory myositis. It combined a patient's own engineered immune cells (CLBR001) with a targeted antibody drug (SWI019), with or without chemotherapy-like lymphode…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new treatment called Prula-cel for people with certain autoimmune diseases like lupus and scleroderma. Prula-cel uses specially engineered immune cells from a healthy donor to target and attack faulty immune cells that cause disease. The main goals …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated May 08, 2026 12:02 UTC